# ACOREP

Type: regulatory_body

Source: Biotech Intelligence Brief — https://getbiobrief.com/entity/acorep
Canonical HTML page: https://getbiobrief.com/entity/acorep

## Timeline

- **2026-07-13**: Ethics Approval Received — NanoViricides announces National Ethics Committee approval for Phase II trial of NV-387 oral gummies for Ebola.
- **2026-07-12**: Outbreak Worsens — DRC public health institute reports 1,926 confirmed Ebola cases and 702 deaths, with spread to Haut-Uele and Tshopo provinces.

## Recent coverage (1 stories)

### NNVC's NV-387 Phase II Sets Course as First Oral Ebola Therapy Contender
2026-07-13 19:35:03 · Sentiment: Positive · Impact: 7/10 · Sources: 3

NanoViricides (NYSE American: NNVC) has crossed a major regulatory hurdle with DRC ethics committee approval for its Phase II trial of NV-387 oral gummies for Ebola. The company leverages its nanoviricide platform against an underserved Bundibugyo strain, positioning itself uniquely in the infectious disease space with a potential first-in-class oral antiviral.
Full story: https://getbiobrief.com/story/nanoviricides-nnvc-oral-ebola-phase2

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getbiobrief.com/guides/methodology for the full editorial methodology.